Connect with us

Technology

bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types

Published

on

Researchers can easily track and isolate bit.bio’s consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

ioTracker Cells, the new range within bit.bio’s ioCells portfolio, deliver added visualisation capabilities that enhance the portfolio of deterministically-programmed human iPSC-derived cells powered by opti-ox™.The first product in this range, GFP ioMicroglia, is derived from bit.bio’s industry-leading wild-type ioMicroglia and retains their consistent, defined, and highly functional properties. It is specifically designed to track and isolate cells in complex in vitro cultures and in vivo settings, enabling a deeper understanding of intercellular interactions in neurodegenerative diseases.Microglia are the primary responders to signals of brain injury or disease, and their activation and movement patterns are frequently studied in conditions such as Alzheimer’s, Parkinson’s, and other neurodegenerative and neuropsychiatric diseases.

CAMBRIDGE, United Kingdom, Jan. 27, 2025 /PRNewswire/ — bit.bio, the global leader in cell programming technology, today announces the launch of its ioTracker Cells range, starting with GFP ioMicroglia, a progressive tool designed to accelerate complex neurodegenerative disease research and drug discovery. This innovative new range represents a strategic expansion of bit.bio’s ioCells Toolkit, introducing advanced live-cell imaging assay capabilities to further enhance the functionality of its flagship products.

bit.bio will showcase its portfolio of human iPSC-derived cells at the Society for Laboratory Automation and Screening (SLAS) conference, taking place from January 25-29, 2025, in San Diego, California. The bit.bio team will be at Booth #851, present multiple poster sessions and host a panel discussion with industry experts, highlighting real-world applications on how its cells are transforming drug discovery workflows.

“With ioTracker Cells, we are empowering researchers to unravel the complexities of the human brain,” said Jonathan Milner, CEO of bit.bio. “This new range, starting with GFP ioMicroglia, reflects our mission to deliver transformative tools for biomedical research and drug discovery. Our cells are accessible to scientists worldwide through global shipping, providing a comprehensive toolkit to accelerate discoveries that have the potential to transform the understanding and treatment of devastating neurological diseases.”

bit.bio’s ioCells are human iPSC-derived cells, manufactured using the company’s deterministic cell programming technology, opti-ox™. They are widely recognised as best-in-class for their unparalleled consistency, functionality, and scalability. The ioCells portfolio now features 46 products, including ioWild Type Cells, ioDisease Model Cells, ioCRISPR-Ready Cells, and the newly introduced ioTracker Cells.

“With GFP ioMicroglia, we’re simplifying cell visualisation in complex model systems,” said Mark Kotter, Founder of bit.bio. “We are committed to relentlessly innovating cellular tools that enable scientists to study human biology and disease. I look forward to learning how our customers will use our ioTracker cells to enable novel scientific breakthroughs.”

GFP ioMicroglia are engineered to constitutively express green fluorescent protein (GFP) in bit.bio’s well-established ioMicroglia Male wild type cells. These cells demonstrate key functionalities including phagocytosis and pro-inflammatory cytokine secretion. Assay-ready in just 10 days, GFP ioMicroglia are ideal for co-culture with other neural cell types, live-cell imaging assays to simplify assessment of microglia motility and morphology, and fluorescent activated cell sorting (FACS) workflows.

“bit.bio’s new ioTracker Cells range represents a valuable addition to our neuroscience toolkit,” said Farah Patell-Socha, Vice President of Products at bit.bio. “These cells offer researchers a more refined approach to studying neuroinflammation, neurogenesis, and neurodegenerative processes. By enabling precise tracking and isolation in complex in vitro cultures, they facilitate a deeper understanding of intercellular interactions in disease. Combined with our CRISPR-Ready cells, disease models, and genetically-matched controls, these tools provide a comprehensive foundation for advancing neurodegenerative disease research.”

For more information or to purchase bit.bio’s GFP ioMicroglia, please visit our ioCells Product catalogue.

About bit.bio

bit.bio designs and manufactures human cells to advance drug discovery and biomedical research enabling transformative treatments in human health. Using our proprietary deterministic cell programming technology, opti-ox, our aim is to convert any induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. Using our AI-powered discovery platform, we are working towards identifying unique combinations of transcription factors that can program any desired cell type with exceptional purity and consistency at scale, with products ready to ship globally. To date, bit.bio’s ioCells portfolio features eight differentiated cell types and 38 derivative products including ioWild Type Cells, ioDisease Model Cells, ioTracker Cells and ioCRISPR-Ready Cells.

Since spinning out from the University of Cambridge and launching in 2016, we have raised approximately $225m from leading investors, including Arch Venture, Blueyard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent.

For more information, please visit: www.bit.bio
For information on bit.bio’s trademarks, visit www.bit.bio/trademarks
LinkedIn: https://www.linkedin.com/company/bitbioltd/

Media Contact:

Chris Hempel
Spark Public Relations
chris.hempel@sparkpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bitbio-launches-iotracker-cells-range-at-slas-2025-adding-new-visualisation-functionality-to-human-ipsc-derived-cell-types-302360373.html

SOURCE bit.bio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Wistron Celebrates Grand Opening of First U.S. Smart Factory Marking Milestone in Global Smart Manufacturing Strategy

Published

on

By

FORT WORTH, Texas, July 21, 2026 /PRNewswire/ — Wistron Corporation (“Wistron”) celebrated the grand opening of its D1 AI smart facility in Fort Worth, Texas, the site where the first NVIDIA GB300 Grace Blackwell Ultra Superchip was built and mass-produced in the United States. The US$ 700 million facility, spanning approximately 324,000 square foot, was officially unveiled during a ceremony led by Wistron Chairman Simon Lin and NVIDIA Founder and CEO Jensen Huang. Jessica Rogers, Director of the Economic Development Department for the City of Fort Worth, and Alexander Tah-ray Yui, Taiwan’s Representative to the United States, were among the government officials and business leaders who attended, marking a milestone in the expansion of Wistron’s global footprint and advanced manufacturing capabilities.

This is a key hub in Wistron’s global AI infrastructure manufacturing network. The facility runs on NVIDIA accelerated computing and integrates NVIDIA’s Nemotron and Cosmos open frontier models and Omniverse and Metropolis libraries, using digital twin technology to optimize factory design, production workflows, and operational efficiency. It is Wistron’s first U.S.-based manufacturing facility, established to serve customers locally and produce NVIDIA’s most advanced and cutting-edge products. Wistron Chairman Simon Lin said “The operation here is not typical manufacturing. It is new, very comprehensive, and high-tech. Right now we produce the NVIDIA GB300 Grace Blackwell Ultra Superchip, and beyond, we are also going to produce the NVIDIA Vera Rubin Superchip here. In the next couple of years, this location will be one of the most important, as we build AI infrastructure here in the United States. I think this is the reason we say that there will be the next chapter, and we are going to empower AI from Texas.”

Responding to Customer Needs: Texas, the Newest Global Manufacturing Hub
At this pivotal moment for global AI infrastructure, Wistron is drawing on decades of global manufacturing experience to expand its footprint in Texas, a state with a well-established ecosystem for logistics, talent recruitment, and advanced manufacturing. The new D1 facility produces the NVIDIA GB300 Grace Blackwell Ultra Superchip and soon, the NVIDIA Vera Rubin Superchip — critical to powering the next generation of AI computing. The new Fort Worth facility strengthens a critical upstream layer of the AI infrastructure supply chain by expanding domestic capacity to assemble and test NVIDIA AI systems. These servers can be integrated into NVIDIA DSX infrastructure, with DSX providing the common architecture and technologies needed to deploy and operate energy-efficient AI factories at scale.

One-Stop Operational Ecosystem Strengthens U.S. AI Supply Chain Resilience
Behind every breakthrough in AI computing lies the manufacturing capability to scale it. Wistron is expanding its AI server production capabilities from Taiwan to the United States, guided by a vision of precision, efficiency, and sustainability. This reflects a broader industry shift: AI leadership is determined not only by technological breakthroughs, but also by the operational capability to transform innovation into high-volume production with consistent quality, supply chain resilience, and predictable delivery. By establishing AI infrastructure manufacturing capacity in the United States, Wistron is building a one-stop operational ecosystem spanning manufacturing and after-sales service — shortening delivery timelines and customer support cycles, strengthening supply chain resilience, and laying the foundation for long-term competitive advantage as AI infrastructure continues to scale.

Partnering with NVIDIA to Pioneer a New Model for Smart Manufacturing and Energy Optimization
As the era of physical AI begins, Wistron is extending its smart manufacturing capabilities to the United States, creating a new model for AI infrastructure production built on digital manufacturing, energy optimization, and local operations. Jensen Huang said: “The largest infrastructure buildout in history is underway. Demand for AI factories—the engine of this next industrial revolution—is incredible, and they must be produced everywhere. Together, NVIDIA and Wistron are restoring US advanced manufacturing capacity in Texas, creating skilled jobs and strengthening America’s AI supply chain.” As demand for advanced manufacturing grows in Texas, smarter planning of production loads and energy use will give the plant greater control and flexibility over its electricity needs.

Turning Global Experience into Scalable AI Infrastructure
Simon Lin stressed that the speed the AI era demands comes with its own responsibility. “In the AI era, the pressure of speed is also a form of responsibility,” Lin said. “We don’t just need to build fast; we need to build right.”

The Fort Worth plant will serve as the core engine of Wistron’s U.S. manufacturing operations, the company said, connecting its global production network with ecosystem partners as it scales advanced AI manufacturing. Wistron said that the investment reflects efforts to deepen its technical capabilities, strengthen the resilience and efficiency of global supply chains, and support the next phase of AI infrastructure development.

About Wistron:
Wistron Corporation is a leading global technology service provider delivering advanced ICT products, AI infrastructure, and manufacturing solutions to technology brands worldwide. With more than 63,000 employees across North America, Europe, and Asia, Wistron continues to expand its AI, cloud, and advanced manufacturing capabilities to support the next generation of intelligent computing. For more information about Wistron, please visit the official website at www.wistron.com. Additional information about the event is available on the event website.

Media Contact:
Joyce WL Chou
joyce_wl_chou@wistron.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/wistron-celebrates-grand-opening-of-first-us-smart-factory-marking-milestone-in-global-smart-manufacturing-strategy-302831439.html

SOURCE Wistron Corporation

Continue Reading

Technology

NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore

Published

on

By

New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care

SINGAPORE, July 22, 2026 /PRNewswire/ — The NSG Bio Tomorrow initiative aims at supporting emerging life sciences startups working on complex challenges in respiratory and neonatal care.

Launched through the support of Chiesi Group, The Impulse initiative will provide a selected startup with one year of NSG Bio membership and access to a dedicated laboratory bench at NSG Bio Singapore. The initiative is designed to help early-stage biotech companies move from promising science toward stronger proof-of-concept work in a fully equipped research environment.

The initiative comes at a time when the biotech industry is increasingly looking for faster, more connected ways to move high-potential science from the lab toward real-world patient impact. For startups, access to infrastructure is only one part of the challenge. Equally important are the right networks, industry visibility, technical environment, and opportunities to engage with partners who understand the path from early discovery to clinical relevance.

The programme will focus on startups developing innovative biotechnological solutions with potential relevance to chronic respiratory diseases and neonatal conditions. Areas of interest include cell therapies, gene therapies, gene-editing technologies, regenerative tissue engineering, engineered or programmable living systems, lung-targeted delivery platforms, preventive approaches, and small-molecule-based approaches.

The selected startup will gain access to NSG Bio’s laboratory infrastructure, shared workspaces, meeting facilities, and wider community of biotech entrepreneurs, researchers, scientific leaders, and industry partners. The support is intended to help the company advance key research milestones while becoming part of Singapore’s growing life-science innovation ecosystem.

For NSG Bio, the initiative is part of NSG Bio Tomorrow, its ecosystem-building arm created to expand the company’s role beyond facilities and real estate. While NSG Bio is known for providing high-quality laboratory and office infrastructure for biotech companies, NSG Bio Tomorrow focuses on building the programmes, partnerships, and opportunities that help startups grow.

“Biotech companies need more than lab space. They need access, momentum, and the right ecosystem around them,” said Hasyim Sim, Co-Founder and Chief Operating Officer, NSG Bio. “Through NSG Bio Tomorrow, we are building initiatives that help promising startups connect with partners, unlock opportunities, and move their science forward. This initiative reflects exactly the kind of role we want to play in the biotech ecosystem.”

“Chiesi is committed to supporting innovation that can make a meaningful difference for patients, and we work with entrepreneurs, researchers and partners to advance meaningful ideas,” said Fabrizio Conicella, Vice President, Center of Open Innovation & Competence at Chiesi Group. “By supporting this NSG Bio Tomorrow initiative, we want to create an opportunity for early-stage innovators to access the infrastructure and ecosystem support needed to develop impactful science in respiratory and neonatal care.”

NSG Bio Tomorrow programme also reinforces Singapore’s position as a growing hub for biotech innovation in Asia, where startups, research institutions, investors, and industry partners are increasingly coming together to support the next generation of healthcare companies.

Applications open on 22 July 2026 at 09:00 a.m. SGT. Finalists will be invited to present at a virtual pitch event, after which the selected startup will be announced.

About NSG Bio

NSG Bio is Singapore’s leading provider of BSL-2 certified co-working laboratory and office spaces, supporting life-science companies from early research through growth. Through its facilities, community, and ecosystem initiatives, NSG Bio enables biotech innovators to accelerate research, access networks, and build companies that address critical healthcare challenges.

About NSG Bio Tomorrow

NSG Bio Tomorrow is NSG Bio’s ecosystem-building arm, created to support the next generation of biotech innovation through partnerships, programmes, community initiatives, and opportunities that extend beyond physical laboratory infrastructure. Its mission is to strengthen the biotech industry by connecting startups with the resources, expertise, and networks they need to thrive.

About Chiesi Group 

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. 

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit https://www.chiesi.com/en/home 

Media Contact
Giridharan
Laboratory Manager
NSG Bio
giridharan@nsgbio.com
87797175

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/nsg-bio-accelerates-breakthrough-biotech-innovation-in-singapore-302830494.html

SOURCE NSG Bio

Continue Reading

Technology

House Judiciary Committee Passes Bill that Would Prevent Future Immigration Crises: Swift Action Needed by Full House, Says FAIR

Published

on

By

WASHINGTON, July 21, 2026 /PRNewswire/ — Today, the House Judiciary Committee passed an updated version of H.R. 2, the landmark border security bill from last congressional session. The bill now awaits consideration by the full House of Representatives. The Federation for American Immigration Reform (FAIR) urges Speaker Mike Johnson to schedule a final floor vote as soon as possible.

The Secure Border Act systematically closes the loopholes that allowed the Biden administration to unleash the largest and most damaging wave of illegal immigration in American history. Enactment of this legislation would prevent future anti-borders administrations from shirking their responsibilities to secure our borders and enforce our immigration laws; asserting unlimited discretion to parole inadmissible aliens to enter the country; or releasing millions of illegal aliens into the country, rather than detaining them or returning them to the country from which they entered.

“We congratulate the Judiciary Committee for its swift action on this critical legislation,” said Dale Wilcox, executive director and general counsel of FAIR. “Ending border chaos and rampant illegal immigration was a key reason that Republicans regained control of the White House and both chambers of Congress in the last election. The clock is ticking on the 119th Congress, and Republicans only have a short time to deliver on the promises they made to voters in 2024, before the midterms.

“Right now, our immigration laws are being enforced in the interests of the American people. As the last administration demonstrated, enforcement of those laws is not guaranteed unless Congress acts to prevent similar abuse in the future. Now is the time for decisive action in the House, where this bill can be passed with a simple majority vote, and an opportunity for Senate Majority Leader John Thune to put every member of that body on record before voters go to the polls in the fall,” Wilcox concluded.

Hayley Hill, hhill@fairus.org 202-328-7004

View original content to download multimedia:https://www.prnewswire.com/news-releases/house-judiciary-committee-passes-bill-that-would-prevent-future-immigration-crises-swift-action-needed-by-full-house-says-fair-302831443.html

SOURCE Federation for American Immigration Reform (FAIR)

Continue Reading

Trending